BVF INC/IL
CIK 1056807 · last filed 2026-06-22
BVF INC/IL is a corporate insider who has filed 38 SEC Form 4 insider transactions across 25 companies since 2008. The most recent filing, for MLTX, was dated Jun 22, 2026. Across all open-market trades the lifetime net is +$10.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.17B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.17B
25
38
$10.09M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MLTX | Director | 6,599,722 | $18.71 | $123.48M | $0 | 1 | 2026-06-22 |
| XOMAP | 10%+ Owner | 3,545,545 | $24.98 | $88.57M | $0 | 2 | 2026-05-18 |
| OLMA | Director | 2,103,522 | $11.62 | $24.44M | $0 | 1 | 2025-06-13 |
| ELDN | 10%+ Owner | 2,633,679 | $3.40 | $8.95M | $0 | 1 | 2024-10-31 |
| KYMR | Director | 294,632 | $106.16 | $31.28M | $41.50M | 2 | 2024-01-09 |
| Third Harmonic Bio, Inc. (THRD) Delisted | 10%+ Owner | 2,332,638 | $5.38 | $12.55M | $8.79M | 1 | 2022-12-22 |
| CTI BIOPHARMA CORP (CTIC) Delisted | 10%+ Owner | 1,784,461 | $9.09 | $16.22M | $133.00M | 2 | 2022-03-11 |
| CYTK | 2,760,185 | $79.45 | $219.30M | -$77.57M | 1 | 2020-12-11 | |
| Merus N.V. (MRUS) Delisted | 10%+ Owner | 2,200,035 | $90.00 | $198.00M | $17.24M | 1 | 2020-09-17 |
| IDYA | 10%+ Owner | 1,204,981 | $36.16 | $43.57M | $337.0K | 1 | 2020-07-02 |
| Calithera Biosciences, Inc. (CALA) Delisted | 10%+ Owner | 32,927 | $0.00 | $10 | $3.03M | 1 | 2019-11-18 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 2,958,503 | $38.00 | $112.42M | $27.11M | 1 | 2019-11-07 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | 10%+ Owner | 9,654 | $13.60 | $131.3K | $0 | 1 | 2019-02-01 |
| XOMA | 10%+ Owner | 355,527 | $40.17 | $14.28M | $6.28M | 1 | 2018-12-10 |
| XENE | 10%+ Owner | 297,464 | $64.94 | $19.32M | $1.82M | 1 | 2017-06-30 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 3,627,610 | $0.04 | $162.2K | $6.94M | 1 | 2016-12-30 |
| LGND | 10%+ Owner | 2,008,834 | $296.28 | $595.18M | -$303.29M | 4 | 2013-11-29 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | 10%+ Owner | 4,555,829 | — | — | $2.95M | 1 | 2013-08-02 |
| CAPS | 10%+ Owner | 3,522 | $0.25 | $875 | $446.7K | 1 | 2011-07-18 |
| Celera CORP (CRA) Delisted | 10%+ Owner | 38,163,934 | — | — | $167.43M | 2 | 2011-05-17 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | 10%+ Owner | 1,179,292 | $15.50 | $18.28M | -$5.05M | 3 | 2009-08-03 |
| RPRX | 10%+ Owner | 2,740,026 | $59.97 | $164.32M | -$7.29M | 1 | 2009-07-15 |
| RGEN | 10%+ Owner | 5,795,100 | $145.34 | $842.26M | -$14.95M | 1 | 2009-07-08 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 10%+ Owner | 8,308,999 | — | — | $251.8K | 2 | 2008-11-25 |
| AVIGEN INC \DE (AVGN) Delisted | 10%+ Owner | 8,055,315 | — | — | $1.12M | 1 | 2008-11-13 |
Recent Filings
38 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-22 | MLTX | Grant (A) | — | $0 | EDGAR |
| 2026-05-18 | XOMAP | Conv (C) | +50,030,000 | $201.62M | EDGAR |
| 2025-06-13 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2024-10-31 | ELDN | Buy (P) | — | $0 | EDGAR |
| 2024-01-09 | KYMR | Buy (P) | — | $0 | EDGAR |
| 2022-12-22 | Third Harmonic Bio, Inc. (THRD) Delisted | Buy (P) | +2,140,630 | $8.79M | EDGAR |
| 2022-05-31 | KYMR | Buy (P) | +2,894,260 | $41.50M | EDGAR |
| 2022-03-11 | CTI BIOPHARMA CORP (CTIC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-21 | XOMAP | Grant (A) | — | $0 | EDGAR |
| 2020-12-11 | CYTK | Sell (S) | −4,309,540 | -$77.57M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.